Head and Neck Squamous Cell Cancer Clinical Trial
Official title:
A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719
Single centre, single arm, preoperative window of opportunity study with a biomarker endpoint (expression profiling by RNA sequencing). Patients with resectable, histologically confirmed head and neck squamous cell carcinoma (HNSCC) for whom surgical treatment is planned as definitive management will be eligible.
This is a single centre, single arm, preoperative window of opportunity study with a biomarker endpoint (expression profiling by RNA sequencing). Patients with resectable, histologically confirmed head and neck squamous cell carcinoma (HNSCC) for whom surgical treatment is planned as definitive management will be eligible. The median time from consultation to major head and neck surgery at our institution is 3.2 +/- 2.0 weeks (1 standard deviation). To provide the maximal opportunity to achieve a biomarker response and potentially observe clinical responses, patients will receive BYL719 orally daily at the maximum tolerated dose (400 mg/day) for 14 days. All patients will receive surgery as the standard of care. The gene expression profile, including Ki-67, from the surgical specimen and mandatory baseline tumor biopsy will be evaluated for primary and secondary pharmacodynamic endpoints. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03667482 -
Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
|
Phase 1 | |
| Completed |
NCT02083692 -
Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling
|
Early Phase 1 | |
| Completed |
NCT02282371 -
Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)
|
Phase 1 | |
| Active, not recruiting |
NCT02159508 -
Intensive Nutrition Counselling in Patients With Head and Neck Cancer
|
N/A | |
| Completed |
NCT02252042 -
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
|
Phase 3 | |
| Terminated |
NCT01790516 -
Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer
|
N/A | |
| Completed |
NCT00574977 -
Safety Study of Modified Vaccinia Virus to Cancer
|
Phase 1 | |
| Completed |
NCT00592371 -
Head and Neck Cancer Screening and Serum Repository
|
N/A | |
| Recruiting |
NCT02485548 -
Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer
|
Phase 3 | |
| Terminated |
NCT01326923 -
Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT03975270 -
Sintilimab in Combination With Nab-paclitaxel in Patients With HNSCC (Head and Neck Squamous Cell Carcinoma )
|
Phase 2 | |
| Terminated |
NCT04187872 -
LITT and Pembrolizumab in Recurrent Brain Metastasis
|
Phase 1 | |
| Recruiting |
NCT02327468 -
Inovio TRT-001: Telomerase DNA Immunotherapy in Breast, Lung, and Pancreatic Cancers
|
Phase 1 | |
| Active, not recruiting |
NCT01351103 -
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
|
Phase 1 | |
| Terminated |
NCT00260598 -
LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer
|
Phase 2 | |
| Completed |
NCT02163057 -
Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04856631 -
A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer
|
Phase 1/Phase 2 |